AP NEWS

Global Cervical Dystonia Therapeutics Market 2019-2023| Expected Approval of Late-Stage Pipeline Molecules to Boost the Market| Technavio

November 8, 2018

LONDON--(BUSINESS WIRE)--Nov 8, 2018--The global cervical dystonia therapeutics market 2019-2023 is expected to post a CAGR of close to 5% during the forecast period, according to the latest market research report by .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181108005322/en/

Technavio predicts the global cervical dystonia therapeutics market to post a CAGR of close to 5% by 2023. (Graphic: Business Wire)

A key factor driving the growth of the market is expected approval of late-stage pipeline molecules. Despite the significant research undertaken over the past several decades, the treatment that is promising and having fewer side effects is not yet available for the treatment of cervical dystonia. This is encouraging pharmaceutical companies to focus on the development of promising therapeutics for the treatment of cervical dystonia. As the market currently witnessing an acute lack of more approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the cervical dystonia patient pool. Once these molecules are launched over the forecast period, the global cervical dystonia therapeutics market should witness strong value growth from these newly launched therapeutics.

This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.

This report is available at a USD 1,000 discount for a limited time only:

In this report, Technavio highlights reimbursement for botulinum neurotoxin injections as one of the key emerging trends in the global cervical dystonia therapeutics market:

Global cervical dystonia therapeutic market: Reimbursement for botulinum neurotoxin injections

Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins. Additionally, the cervical dystonia fund is dedicated to assist insured patients who cannot afford the out-of-pocket costs associated with any US FDA approved treatment for cervical dystonia. Thus, several reimbursement programs aid the eligible patients for the high-cost botulinum toxins treatment and thus boost the global cervical dystonia market growth over the forecast period.

“Allergan, the manufacturer of BOTOX, sponsors a comprehensive reimbursement program called as BOTOX reimbursement solutions program which assists patients who are receiving Botox injection treatment. Also, Ipsen CARES program is designed to help patients get access to disport therapy for the treatment of cervical dystonia. These reimbursement programs aid the patients,” says a senior analyst at Technavio for research on infectious and rare diseases.

Global cervical dystonia therapeutics market: Segmentation analysis

This market research report segments the global cervical dystonia therapeutics market by product (botulinum toxins and other therapeutics) and geographical regions (APAC, EMEA, and the Americas).

The Americas led the market in 2018 with a market share of more than 41%, followed by EMEA and APAC respectively. The dominance of the Americas can be attributed to the expected approval of late-stage pipeline molecules and increasing awareness about cervical dystonia.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181108005322/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 11/08/2018 11:01 AM/DISC: 11/08/2018 11:00 AM

http://www.businesswire.com/news/home/20181108005322/en

AP RADIO
Update hourly